|
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation |
Thompson Coon J, Hoyle M, Green C, Liu Z, Welch K, Moxham T, Stein K |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Thompson Coon J, Hoyle M, Green C, Liu Z, Welch K, Moxham T, Stein K. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technology Assessment 2010; 14(2): 1-208 Indexing Status Subject indexing assigned by CRD MeSH Angiogenesis Inhibitors; Antibodies, Monoclonal; Carcinoma, Renal Cell; Cost-Benefit Analysis; Humans; Indoles; Markov Chains; Protein Kinase Inhibitors; Pyrroles; Quality-Adjusted Life Years; Sirolimus AccessionNumber 22010000214 Date bibliographic record published 31/03/2010 |
|
|
|